Table 1.
Demographics and oncological characteristics of eligible patients according to the vaccination status.
| Unvaccinated |
Fully vaccinated |
P-value | Partially vaccinated |
|
|---|---|---|---|---|
| N = 1930 (%) | N = 91 (%) | N = 69 (%) | ||
| Country | ||||
| United Kingdom | 607 (31.5) | 45 (49.5) | 0.0003 | 35 (50.7) |
| Spain | 712 (36.9) | 32 (35.2) | 26 (37.7) | |
| Italy | 611 (31.7) | 14 (15.4) | 8 (11.6) | |
| Sex | ||||
| Male | 1043 (54.2) | 43 (47.3) | 0.1970 | 35 (50.7) |
| Females | 883 (45.8) | 48 (52.7) | 34 (49.3) | |
| Missing | 4 | – | – | |
| Age | ||||
| <65 years | 753 (39.2) | 44 (48.4) | 0.0798 | 26 (38.8) |
| ≥65 years | 1170 (60.8) | 47 (51.6) | 41 (61.2) | |
| Missing | 6 | – | 2 | |
| Comorbidities | ||||
| 0–1 | 1031 (53.4) | 48 (52.7) | 0.9000 | 32 (46.4) |
| ≥2 | 899 (46.6) | 43 (47.3) | 37 (53.6) | |
| Smoking history | ||||
| Never smokers | 818 (50) | 34 (41) | 0.1095 | 24 (41.4) |
| Former/current smokers | 819 (50) | 49 (59) | 34 (58/6) | |
| Missing | 293 | 8 | 11 | |
| Primary Tumour | ||||
| Breast | 313 (16.4) | 16 (17.6) | 0.5284 | 13 (18.8) |
| Gastrointestinal | 385 (20.1) | 15 (16.5) | 12 (17.4) | |
| Gynaecological/Genito-Urinary | 344 (18.0) | 21 (23.1) | 13 (18.8) | |
| Thoracic | 301 (15.7) | 15 (16.5) | 13 (18.8) | |
| Others | 225 (11.8) | 13 (14.3) | 10 (14.5) | |
| Haematologic | 346 (18.1) | 11 (12.1) | 8 (11.6) | |
| Missing | 16 | – | – | |
| Tumour stage | ||||
| Local/loco-regional | 833 (47.2) | 34 (40) | 0.1959 | 31 (47) |
| Advanced | 933 (52.8) | 51 (60) | 35 (53) | |
| Missing | 164 | 6 | 3 | |
| Tumour status at COVID-19 diagnosis | ||||
| Remission/non measurable disease | 679 (35.5) | 30 (33) | 0.6249 | 27 (39.7) |
| Active malignancy | 1235 (64.5) | 61 (67) | 41 (60.3) | |
| Missing | 16 | – | 1 | |
| SACT at COVID-19 diagnosisa | ||||
| No | 1103 (59.7) | 40 (45.5) | 0.0082 | 33 (53.2) |
| Yes | 746 (40.3) | 48 (54.5) | 29 (46.8) | |
| Missing | 81 | 3 | 7 | |
| Timing of infection | ||||
| Post-vaccination phase | 560 (29.0) | 91 (100) | 69 (98.6) | |
| Pre-vaccination phase | 1370 (71.0) | – | – | |
SACT: systemic anticancer therapy.
a
Within 4 weeks prior to COVID-19 diagnosis.